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Abstract
Background: Throughout Africa, many people seek care for malaria in private-sector drug shops where diagnostic testing is
often unavailable. Recently, subsidized artemisinin-based combination therapies (ACTs), a first-line medication for
uncomplicated malaria, were made available in these drug shops in Tanzania. This study assessed the prevalence of malaria
among and purchase of ACTs by drug shop clients in the setting of a national ACT subsidy program and sub-national drug
shop accreditation program.
Method and Findings: A cross-sectional survey of drug shop clients was performed in two regions in Tanzania, one with a
government drug shop accreditation program and one without, from March-May, 2012. Drug shops were randomly
sampled from non-urban districts. Shop attendants were interviewed about their education, training, and accreditation
status. Clients were interviewed about their symptoms and medication purchases, then underwent a limited physical
examination and laboratory testing for malaria. Malaria prevalence and predictors of ACT purchase were assessed using
univariate analysis and multiple logistic regression. Amongst 777 clients from 73 drug shops, the prevalence of laboratory-
confirmed malaria was 12% (95% CI: 6–18%). Less than a third of clients with malaria had purchased ACTs, and less than a
quarter of clients who purchased ACTs tested positive for malaria. Clients were more likely to have purchased ACTs if the
participant was ,5 years old (aOR: 6.6; 95% CI: 3.9–11.0) or the shop attendant had .5 years, experience (aOR: 2.8; 95% CI:
1.2–6.3). Having malaria was only a predictor of ACT purchase in the region with a drug shop accreditation program (aOR:
3.4; 95% CI: 1.5–7.4).
Conclusion: Malaria is common amongst persons presenting to drug shops with a complaint of fever. The low proportion of
persons with malaria purchasing ACTs, and the high proportion of ACTs going to persons without malaria demonstrates a
need to better target who receives ACTs in these drug shops.
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Introduction
Malaria is one of the leading causes of death in children under
five years of age and accounts for up to 40% of outpatient visits in
Tanzania [1,2]. The World Health Organization (WHO) has
recommended that persons with malaria receive effective antima-
larial treatment within 24 hours of symptom onset, in order to
avoid progression to severe disease [3]. This target has been
difficult to achieve in Tanzania, where the proportion of children
under five with fever who received a first-line antimalarial within
one day of symptom onset was just 26% in 2010 [4].
Studies throughout sub-Saharan Africa have shown that the
private sector is commonly utilized as an initial source of treatment
for malaria or fever [5]. In addition to private health facilities and
clinics, this includes pharmacies, drug shops, and general retail
stores that sell medicines. While pharmacies are staffed by licensed
pharmacists and are permitted to sell prescription-only-medicines,
drug shops can be operated by a wide range of providers and have
historically been permitted to sell mostly over-the-counter
medicines in Tanzania [6]. In 2010, a household survey in three
regions in Tanzania, found that of those who sought care for fever
in the prior 14 days, 41% sought care at a pharmacy, drug shop,
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or general store, whereas only 19% went to a government health
facility [7].
Patients may choose to seek care in the private retail sector over
the public sector for multiple reasons including convenience (hours
open), accessibility (proximity to home), reliability of medication
stocks, and ability to negotiate the cost of care [6,8–10]. At the
same time, studies have documented multiple substandard
practices in these shops such as dispensing medications that do
not treat the client’s illness or are ineffective because of widespread
resistance, dispensing medicines in insufficient quantities, provid-
ing inadequate medication instructions, and even dispensing
medicines that are counterfeit or of substandard quality
[5,6,8,11–13].
The opportunities and risks related to retail sector medicine
provision have led to the development of a number of initiatives to
strengthen the provision of care in drug shops. In Tanzania, key
strategies have included the Accredited Drug Dispensing Outlet
(ADDO) program and the Affordable Medicines Facility-malaria
(AMFm). The Tanzanian government began implementing the
ADDO program in 2003. As part of this initiative, drug shop
owners apply to have their shops accredited by the government
and then undergo a certification process. Drug shop dispensers
must attend a 35 day training course, covering key areas such as
family planning, malaria treatment and other common illnesses.
Shops certified as ADDOs are permitted to sell a limited range of
prescription-only-medicines including the artemisinin-based com-
bination therapy (ACT) artemether-lumefantrine (AL), the first-
line option for uncomplicated malaria in Tanzania. The program
also aims to use increased regulation and business incentives to
support best practices [14,15]. Between 2003 and 2011, ADDO
certification and training was completed in over 3,800 drug shops
in 15 out of 21 regions in Tanzania [14].
The AMFm aimed to expand access to ACTs in the public and
private sectors. ACTs became first-line for uncomplicated malaria
in Tanzania in 2006, due to widespread resistance to chloroquine
and sulfadoxine-pyrimethamine (SP). Although ACTs are more
effective than these older antimalarials, they were initially up to
10–20 times the price, leading to concern that persons seeking
malaria care in the private sector would continue purchasing
cheaper medicines that were no longer recommended [16].
Hosted by the Global Fund to Fight AIDS, Tuberculosis and
Malaria (Global Fund), AMFm was designed to address this
problem, by using negotiated procurement and subsidization of
ACTs upon purchase from manufacturers to increase ‘‘the
affordability, availability, market share and use of quality assured
ACTs’’ in public and private markets [17–20]. It was piloted at
national scale in seven countries, with AMFm-subsidized ACTs
first becoming available in mainland Tanzania in late 2010 [20].
One final intervention which may have influenced the use of the
drug shops for malaria management was the roll-out of rapid
diagnostic tests (RDTs) for malaria diagnosis. RDTs were rolled
out in Tanzanian public health facilities from 2010–2012. All
patients are now expected to undergo parasitological diagnosis
prior to antimalarial treatment, in accordance with WHO
guidelines [21]. However, diagnostic testing in the retail sector
was officially prohibited, and fewer than 1% of drug shops stocked
RDTs in 2011 [20]. As a result, there has been concern that
subsidized ACTs sold in drug shops do not necessarily benefit
persons who have malaria [22–24]. While baseline and endline
outlet surveys conducted under an independent evaluation
demonstrated that AMFm was successful at decreasing the price,
increasing the availability and increasing the market-share of
quality assured ACTs in the Tanzanian private sector, the degree
to which subsidized ACTs in the private sector were successfully
targeted to those with malaria parasitemia was not assessed
[17,20].
In 2004, a study in one district in Tanzania found a malaria
prevalence of 24% amongst drug shop clients presenting with a
complaint of malaria or fever [25]. This was higher than the 11%
malaria prevalence detected by a contemporaneous random
survey of healthy individuals in the same communities, but was
not significantly different than the 30% malaria prevalence noted
in febrile patients in health facilities in the same district. Only 17%
of drug shop clients in that study obtained a medication with
antimalarial activity and only 9% purchased SP, the first-line
medication for malaria at that time [25]. However, similar data
have not been collected since the implementation of ACT
subsidies.
Given the questions regarding the performance of drug shops in
the management of malaria in Tanzania, this study was designed
to assess the current prevalence of malaria in drug shop clients;
ACT purchasing patterns among drug shop clients; and predictors
of ACT purchase in the setting of ACT subsidies, in areas with and
without ADDO certification.
Methods
Ethics Statement
All drug shop attendants were provided with a full explanation
of the study in the language of their choice, English or Swahili.
They were also informed that this study was being performed for
educational and policy purposes only, that participation was not
required, and that there would be no adverse consequences should
they choose not to participate. Written informed consent was
required before the drug shop could be enrolled in the study. If
consent was not obtained, the research team was not permitted to
record information about the drug shop or recruit clients from that
shop.
When recruiting clients, research staff again had to explain the
purpose of the study, risk and benefits of participation, and
freedom to decline participation at any time to all potential
participants. Written informed consent was required for all
participants over the age of 18. Children under the age of 18
required the written consent of a guardian to participate and
assent was requested of children age 7 to 18. Each participant
signed two copies of the form, one copy which they were allowed
to keep, and one which was kept by the research team as
documentation of consent.
All study procedures and consent forms were submitted to and
approved by the institutional review boards at the Tanzanian
National Medical Research Institute (Dar es Salaam, Tanzania),
Ifakara Health Institute (Dar es Salaam, Tanzania), Centers for
Disease Control and Prevention (Atlanta, GA, USA), and London
School of Hygiene and Tropical Medicine (London, UK).
Study Design
We performed a cross-sectional survey of drug shops in two
regions in Tanzania, Mtwara and Mwanza (Figure 1). These
regions were selected to correspond with other studies in
households, health facilities, drug stores and pharmacies around
the same time. Data collection occurred in Mtwara from March
2–26, 2012, and in Mwanza from April 5-May 2, 2012. Both
regions experience moderate to high malaria endemicity. Amongst
children aged 6–59 months tested for malaria as part of a national
household survey during 2011–2012, 17.4% tested positive by
RDT and 2% tested positive by microscopy in Mtwara, while in
Mwanza, 18.6% tested positive by RDT and 5.4% by microscopy
[26]. This can be compared to a nationwide malaria prevalence of
Tanzania Drug Shop Malaria Parasitemia Study
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9% by RDT and 4% by microscopy amongst children age 6–59
months in the same survey. At the time of the study, the ADDO
program was implemented in the region of Mtwara in 2007 but
had not yet been introduced in Mwanza.
Sampling and Recruitment
Drug shop clients were sampled by stratified, randomized
cluster sampling. The sample size was calculated using the
expected malaria prevalence in drug shop clients as the primary
outcome. Based on a conservative estimated malaria prevalence of
42%, precision of 0.10, power of 80%, and design effect of two, we
calculated a required sample size of 187 per stratum in order to
measure malaria prevalence with 95% confidence. In order to be
able to stratify the data into clients ,5 and clients .5 years, we
aimed to sample at least 374 clients per region.
The Tanzanian Food and Drug Authority (TFDA) provided
lists of all registered drug shops in each region. Drug shops in the
three urban districts (Mtwara Municipality in Mtwara; Nyama-
gana and Ilemela in Mwanza) out of the total 14 districts in the
two regions were excluded to better evaluate health practices in
the private sector in settings with more limited access to public
health facilities. The remaining lists were confirmed with medical
and/or pharmaceutical authorities in each district. A fixed number
of drug shops was randomly sampled from each district to provide
at least 30 shops per region; approximately10 shops per district in
Mtwara and six shops per district in Mwanza. At each district, the
research team visited all selected drug shops and consented drug
shop owners or attendants for participation. Shops that were
closed were visited again a second day. If a drug shop was
identified as permanently or indefinitely closed, a replacement
shop was randomly selected from the list of shops in that district.
In one district the total number of shops was too small to allow for
replacements, and all available shops were included.
Researchers spent one full day at each shop and approached all
clients exiting the shop to assess eligibility for participation after
they had completed their purchase. Clients were considered
eligible for inclusion if they were suspected to have malaria,
defined as having a primary complaint of malaria or fever, or
having purchased an antimalarial or anti-pyretic medication. The
person who was ill or that person’s guardian had to provide
informed consent for participation. If the ill person and/or
guardian were not present at the shop and they resided less than
10 km away, they were consented and interviewed at their home.
For logistical reasons, clients were excluded if the person receiving
the medication was not present at the shop and resided more than
10 km away. Clients were also excluded if the person receiving the
medication was ,3 months of age, pregnant, or showed signs of
severe disease. ACTs are not first-line for any of these groups; as a
result persons in these categories were referred directly to the
nearest health facility, with transportation provided if necessary.
Data Collection and Laboratory Studies
Interviews were performed by clinician researchers, all of whom
had experience caring for malaria patients in the clinical setting in
Tanzania, and who underwent one week of training prior to the
study. Data were captured on personal digital assistants (PDAs)
that included all questions in both English and Swahili. Drug shop
attendant interviews were performed to assess drug shop
accreditation and ownership, as well as drug shop attendant
education, experience and training. Training referred to any in-
service training offered by the government or non-governmental
organizations. Client exit interviews included a brief questionnaire
to assess presenting symptoms, prior health care seeking behaviors
and medications purchased.
Clients also underwent a brief physical examination including
axillary blood temperature, measurement of pulse and respira-
tions, and auscultation of the heart and lungs. They then had a
finger-stick blood sample taken for laboratory studies, including
RDTs (pan-specific ICT Diagnostics, Capetown, South Africa),
blood films and dried blood spots. On-site hemoglobin (Hb) tests
(HemoCue Hb system) were also performed on children under five
years. RDTs and Hb results were read immediately by trained
field staff and appropriate treatment was provided, if the patient
had not already purchased it. These included age appropriate
Figure 1. Map showing Mwanza and Mtwara Regions (Tanzania HMIS, 2008). Reference: Tanzania Comission for AIDS (2008). Tanzania HIV/
AIDS and Malaria Indicatory Survey 2007–08. Dar es Salaam, Tanzania.
doi:10.1371/journal.pone.0094074.g001
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treatment for uncomplicated malaria and anemia according to the
Tanzanian National Guidelines for Diagnosis and Treatment of
Malaria, and basic treatments for acute respiratory illness and
diarrhea according to guidelines for the Integrated Management
of Childhood Illnesses [27,28]. Blood films were stained and filter
paper dried blood spots were prepared by a certified laboratory
technologist in the field. The blood films were then transported to
a central reference laboratory where they were read by two
different laboratory specialists, each blinded to the initial RDT
result as well as the other microscopist’s reading. Discordant
results were resolved by a third microscopist. In addition, if the
final microscopy result differed from the RDT, the filter paper was
used to perform a polymerase chain reaction (PCR) test for
malaria. PCRs were performed by the CDC laboratory using the
Quiagen extraction method, and based on 18 S subunit of
Plasmodium sp. ribosomal RNA. Persons were defined as positive
for malaria if they either had a concordant positive RDT and
blood film, or they had a positive PCR for malaria.
Analysis
Data were analyzed in SAS 9.3 (SAS Institute Inc, Cary, NC).
Univariate analysis of drug shop descriptors and client demo-
graphics was performed both combined and stratified by region. A
wealth index was calculated for participants using a standardized
set of 30 questions assessing the quality of the participants’
housing, access to resources, and items owned. The principal
component function was then used to categorize participants by
wealth quintile. The quintile assigned reflects only relative wealth
internal to the study and not overall wealth compared to other
Tanzanians.
Frequencies were weighted to account for the proportion of
drug shops selected in each district, also accounting for the
proportion of shops within each region that were closed and
needed to be replaced. Because all persons visiting the shop on the
day of the visit were approached for potential inclusion in the
study, the number of persons attending each shop was considered
self-weighting, and no additional adjustments were made for this
in the analysis. Differences between the regions were measured
using chi-squared analysis, or Fisher’s exact tests for tables with
cell values less than five. All p-values were two-tailed, and a p-
value of ,0.05 was considered statistically significant.
Predictors of ACT purchase were assessed using multiple logistic
regression, including all predictors with a p-value of ,0.2 on
bivariate analysis or a suspected effect on the outcome based on
prior studies or logical effect paths. Initial variables assessed
included both drug shop level variables (region, accreditation status,
history of ADDO training, availability of subsidized ACTs, ACT-specific
training, any other in-service trainings, drug shop attendant education, drug
shop attendant years of experience) and client-level variables (age, gender,
wealth quintile, head of household education, history of prior care, visit to a
health facility before arrival, diagnosis of malaria at the health facility, receipt
of prescription at the health facility, chief complaint of fever, fever on exam at
the drug shop, pallor, purchase of paracetamol, purchase of antibiotics).
Correlated variables such as region and drug shop accreditation,
or visit to health facility and malaria diagnosis at the health facility,
were modeled separately. Interactions were also assessed and, if
detected, the model was run with and without a variable
accounting for the interaction. The final model including primary
variables and interactions was chosen based on best model fit
taking into account both the Akaike Information Criterion and
Schwarz’s Bayesian Information Criterion [29,30]. Survey proce-
dures were used to account for district level stratification and drug-
shop level clustering in all analyses, via Taylor series approxima-
tion [31].
Results
In total 73 drug shops were enrolled, 37 in Mtwara and 36 in
Mwanza. The research team approached a total of 1027 clients,
825 of whom were there for malaria or fever. Twenty-six clients
were ineligible for participation because they were aged under 3
months (n = 1), pregnant (n = 9), lived more than 10 km from the
drug-shop (n = 13), were shopping for a client who was not
present, but declined a home visit (n = 2), or did not complete their
eligibility assessment (n = 1). Of the remaining 799 eligible
participants,15 chose not to consent, 7 were excluded due to
signs of severe disease, and 777 were enrolled, 374 in Mtwara and
403 in Mwanza (Figure 2). For forty-two (5%) of these the
research team visited the client at their home in order to complete
the consent and data collection.
Drug Shop Characteristics
Drug shop attendants reported that the shop was ADDO
certified in 96% of shops in Mtwara and none in Mwanza
(Table 1). Availability of subsidized ACTs did not differ
significantly between regions, with 100% of shops in Mtwara
reporting that they carried subsidized ACTs and 81% in Mwanza.
In-service training on ACT use was reported in nearly 59% of
shops in Mtwara, and 19% in Mwanza. Less than a third of
interviewees reported attending other in-service trainings.
There was no significant difference between Mtwara and
Mwanza in either the highest level of education achieved by the
drug shop attendant or the overall years of experience selling
medications. Over half of drug shop attendants had completed
secondary school or obtained a post-secondary school certificate.
Less than 20% had a diploma or degree. Nearly fifty percent of
attendants reported having more than five years of experience
selling medications in both regions.
Client Characteristics
Approximately a quarter of all participants were under five
years while over half were greater than 15 years old in both
Mtwara and Mwanza (Table 2). In both regions, the proportions
of males and females were approximately equivalent. Most
participants came from households where the head of household
had completed primary school, but less than 20% had completed
secondary school or post-secondary school education. Over 90%
of participants in both regions reported having at least one
insecticide-treated bed net in the home.
Healthcare seeking behaviors differed significantly between the
regions, with 24% of clients in Mtwara reporting that they had
previously sought care for their current illness, compared to just
9% of clients in Mwanza. In Mtwara, 14% of clients had been to a
health facility the same day as their visit, whereas in Mwanza only
3% of clients had. Over 70% of these persons had been diagnosed
with malaria and/or provided with a prescription, prior to their
visit to the drug shop.
When asked about their symptoms, over 95% of participants
reported fever. Approximately half complained of cough or
trouble breathing, and a similar amount noted vomiting, diarrhea
or abdominal pain. Headache and runny nose were each reported
by ,10% of clients in each region (Table 3). Fever (temperature
.38uCelsius) was present on examination for 17% of participants
in Mtwara and 11% of participants in Mwanza. Hb levels were
only assessed in participants less than five years of age. In this age
group, mild anemia (Hb 7–11 g/dl) was present in 64% of clients
in Mtwara and 53% of clients in Mwanza. Only 1% in each region
had severe anemia (Hb 5–7 g/dl) and none had life-threatening
anemia (Hb ,5 g/dl).
Tanzania Drug Shop Malaria Parasitemia Study
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Prevalence of Malaria Parasitemia
As noted above, malaria parasitemia was determined by a
combination of tests including RDT, microscopy and PCR
(Figure 3). There were 120 participants with a positive RDT
and 84 participants who tested positive for malaria by microscopy.
In total 101 out of 777 participants tested positive for malaria
parasitemia using the algorithm described above. The prevalence
of malaria parasitemia was highest in children aged 5–14 years,
with a weighted prevalence of 44% (95% CI: 31–57%) in Mtwara
and 21% (95% CI: 2–39%) in Mwanza (Figure 4). There was no
significant difference by region in the prevalence of malaria in the
other age-groups. Approximately 17% (95% CI: 5–28%) of
children under five years and 7% (95% CI: 2–12%) of persons
Figure 2. Client Recruitment.
doi:10.1371/journal.pone.0094074.g002
Table 1. Drug Shop and Drug Shop Attendant Characteristics Stratified by Region.
Variable, n (%) Mtwara (n=37) Mwanza (n =36) P-value
Training and Certification
ADDO certification completed* 35 (96%) 0 (0%) –
Received ADDO training*{ 31 (88%) 0 (0%) –
Sells ACTs that are subsidized by AMFm 37 (100%) 27 (81%) –
Received ACT-specific training*{ 22 (63%) 7 (28%) 0.0181
Received other in-service trainings (not ADDO or ACT){ 12 (31%) 5 (10%) 0.0949
Attendant education (highest level completed) – – 0.3378
Primary school 5 (14%) 7 (20%)
Secondary school 14 (39%) 7 (20%)
Certificate 13 (34%) 15 (42%)
Diploma or degree 5 (13%) 6 (19%)
Attendant experience – – 0.9276
Less than 2 years 5 (15%) 4 (14%)
2–5 years 12 (35%) 14 (41%)
Greater than 5 years 17 (49%) 17 (45%)
{At least one person working in the shop received the training described.
*Weighted proportions differed significantly between regions.
doi:10.1371/journal.pone.0094074.t001
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greater than 15 years tested positive for malaria. The overall
prevalence of malaria was 12% (95% CI: 6–18%).
Medication Purchases
Approximately a third of participants had purchased an
antimalarial for their symptoms, prior to their laboratory
evaluation. In Mtwara, the region with the ADDO-certified
shops, nearly a quarter of participants had purchased ACTs, 80%
of which were subsidized. Purchase of subsidized ACTs was
significantly lower in Mwanza, where just 16% of participants
purchased ACTs (p = 0.0106), 60% of which were subsidized. SP
was purchased by over 10% of clients in each region, and
amodiaquine monotherapy and quinine, were each purchased by
less than 5% of clients in each region. None of the participants
purchased chloroquine or artemisinin monotherapies. Non-anti-
malarial medications included paracetamol, which was purchased
by 71% of clients in Mtwara and 87% of clients in Mwanza, and
antibiotics, which were purchased by 11% of clients in each
region. Table 4 presents the medications purchased in each
region, stratified by malaria status.
Predictors of ACT Purchase
Figure 5 shows the proportion of clients with malaria that
purchased ACTs, stratified by age and region. ACT purchase
amongst clients with malaria was significantly higher in Mtwara
where 44% bought an ACT compared to just 8% in Mwanza (p,
0.0001). A higher proportion of children under five with malaria
received an ACT than any of the other age groups. This was most
pronounced in Mtwara where 73% of children under five with
malaria received an ACT.
Figure 6 shows the prevalence of malaria amongst clients who
purchased ACTs. This also differed significantly between regions.
In Mtwara, the region with the ADDOs, 29% of the participants
that bought ACTs had malaria compared to just 6% in Mwanza
(p = 0.0001). In Mtwara, about 37% of children under 5 and 48%
of children aged 5–14 years whose parents/guardians bought
ACTs had malaria. This was much higher than in Mwanza where
only 8% of children under 5 whose parents bought ACTs had
malaria. Figure 7 presents a graphic representation of the overlap
between patients with malaria and clients purchasing ACTs for
their complaint in the two regions combined.
Table 5 shows the best fit model for predictors of ACT
purchase. Age under five was the most significant predictor with
an adjusted odds ratio (aOR) of 6.6 (95% CI: 3.9–11.0). Other
significant predictors included being seen at a health facility the
day of the visit (aOR: 1.9; 95% CI: 1.0–3.3) and having an
attendant with .5 years of experience (aOR: 2.8; 95% CI: 1.2–
6.3). Purchasing paracetamol or antibiotics negatively predicted
ACT purchase (aOR: 0.3; 95% CI: 0.2–0.4 and aOR 0.4; 95%
CI: 0.2–0.9 respectively). Malaria parasitemia was a significant
predictor of ACT purchase with an aOR of 1.8 (95% CI: 1.0–3.3).
However, there was a significant interaction between malaria
parasitemia and region. Stratifying parasitemia by region demon-
strated that this was driven entirely by Mtwara, where having
malaria parasitemia was a predictor of receiving an ACT with an
aOR of 3.4 (95% CI: 1.5–7.4). In contrast, malaria parasitemia
Table 2. Client Demographics and Health-Seeking Behaviors Stratified by Region.
Variable, n (%) Mtwara (n=374) Mwanza (n =403) P-value
Demographics
Age* – – 0.0408
,5 years 74 (20%) 111 (30%)
5–14 years 47 (13%) 59 (14%)
$15 years 253 (68%) 233 (56%)
Female 177 (48%) 207 (50%) 0.5217
Head of household education – – 0.2243
Did not complete primary school 70 (19%) 93 (25%)
Completed primary school 248 (66%) 251 (61%)
Completed secondary school 52 (15%) 58 (14%)
Bed-net ownership 347 (93%) 378 (95%) 0.3948
Wealth Index (calculated)* 0.5222
Poorest quintile 78 (19%) 75 (19%)
2nd quintile 62 (15%) 91 (22%)
3rd quintile 90 (25%) 67 (19%)
4th quintile 70 (19%) 87 (20%)
Wealthiest quintile 74 (21%) 83 (21%)
Health-Seeking Behaviors
Seen at health facility (HF) same day as drug shop visit* 55 (14%) 19 (3%) 0.0001
Diagnosed with malaria at HF* 46 (12%) 14 (3%) 0.0003
Provided prescription at HF* 46 (12%) 16 (3%) 0.0004
Any prior care this illness* 86 (24%) 36 (9%) ,.0001
Prior antimalarial this illness* 34 (9%) 15 (4%) 0.0123
*Weighted proportions differed significantly between regions.
doi:10.1371/journal.pone.0094074.t002
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was a borderline negative predictor in Mwanza with an aOR of
0.5 (95% CI: 0.2–1.3). Region by itself was not a significant
predictor of ACT purchase (aOR: 1.5; 95% CI: 0.8–2.8).
Discussion
This study assessed ACT purchase in the private sector in the
setting of a national ACT subsidy program and sub-national drug-
Table 3. Client Illness History and Exam Findings Stratified by Region.
Variable, n (%) Mtwara (n =374) Mwanza (n =403) P-value
Presenting Symptoms
Fever 352 (94%) 388 (97%) 0.0669
Cough/trouble breathing* 153 (40%) 211 (55%) 0.0008
Abdominal symptoms 148 (39%) 197 (49%) 0.0711
Headache* 33 (9%) 13 (2%) 0.0003
Runny nose 19 (5%) 22 (5%) 0.9510
Beginning of symptoms – – 0.5861
Same day 26 (7%) 18 (5%)
One day before 148 (39%) 134 (36%)
2–7 days before 178 (48%) 220 (53%)
.7 days before 22 (6%) 31 (6%)
Exam Findings
Fever 66 (17%) 33 (11%) 0.0666
Tachycardia* 31 (8%) 6 (1%) 0.0003
Pallor* 9 (3%) 5 (1%) 0.0183
Course breath sounds 37 (9%) 42 (13%) 0.4687
Abdominal tenderness* 42 (11%) 20 (4%) 0.0005
Hemoglobin Results – – 0.2787
No anemia (Hgb .11g/dl) 27 (34%) 54 (47%)
Mild anemia (Hgb 7–11g/dl) 46 (64%) 56 (53%)
Severe anemia (Hgb ,7g/dl) 1 (1%) 1 (1%)
*Proportions differed significantly between regions.
doi:10.1371/journal.pone.0094074.t003
Figure 3. Total Number of Participants with and without Malaria Parasitemia based on Laboratory (RDT, Microscopy and PCR)
Results. *Malaria parasitemia positive was defined as either concordant RDT and microscopy positive (75) or PCR positive (26) for discordant results.
Malaria parasitemia negative was defined as either microscopy negative without discordance (632) or PCR negative (44) for discordant results.
doi:10.1371/journal.pone.0094074.g003
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shop certification and training program. As in previous studies,
over three-quarters of clients in both regions presented to the drug
shop as their initial source of care. Overall 12% of drug shop
clients with a chief complaint of malaria or fever had malaria
parasitemia. Even in the setting of ACT subsidies, less than a third
of all drug shop clients with malaria obtained ACTs, and most of
the ACTs that were purchased were bought for clients that did not
have malaria.
Surveys of malaria parasitemia prevalence were performed in
health facilities around the same time that this study was being
performed [32]. Malaria prevalence by microscopy among persons
seeking care for malaria was nearly equivalent (11%) in drug shops
and health facilities in Mwanza, where both surveys were
conducted in April–May 2012. In Mtwara, parasitemia prevalence
was twice as high at facilities (15% at drug shops, v. 32% at health
facilities). However, the health facility survey in Mtwara was
performed towards the end of the rainy season (June–July 2012),
when higher malaria parasite prevalence would be expected.
In this study, drug shop clients under five years old were more
likely to have received ACTs than older clients, even when
controlling for prior health care seeking. This likely indicates a
perception of increased risk in this age group, which might be
appropriate given the higher risk of progression to severe disease in
children less than 5 years. However, in both regions malaria test
positivity was highest in school-age children (age 5–14). These
children were three times less likely than their younger counter-
parts to receive the correct medicine if they tested positive for
malaria. This pattern of malaria prevalence, wherein the
prevalence was highest in children age 5–14 was also seen in the
contemporaneous health facility survey mentioned above [32].
This study also demonstrated a difference in ACT targeting
between the two regions, wherein clients with malaria were more
likely to receive ACTs in Mtwara, the region where the ADDO
program had been implemented, than in Mwanza, the region with
uncertified drug shops. Unfortunately, the cross-sectional design of
this study did not allow for full evaluation of the effect of the
ADDO program on provider practices. In addition, ADDO
Figure 4. Malaria Parasitemia Prevalence Stratified by Age and
Region.
doi:10.1371/journal.pone.0094074.g004
Table 4. Proportion of Clients With and Without Malaria Purchasing Antimalarials and Other Medications, Stratified by Region.
Variable, n (%) MTWARA MWANZA
Clients with
malaria (n =61)
Clients without
malaria (n =313) P-value
Clients with
malaria (n =40)
Clients without
malaria (n =363) P-value
Any Antimalarial* 37 (60%) 108 (34%) 0.0008 9 (18%) 118 (32%) 0.1230
ACTs
Artemether-lumefantrine (AL)* 26 (42%) 60 (18%) 0.0004 3 (6%) 45 (12%) 0.1614
Subsidized AL* 22 (35%) 52 (15%) 0.0010 2 (5%) 37 (10%) 0.2208
Artesunate amodiaquine (AA) 1 (1%) 5 (2%) 0.7553 1 (2%) 18 (6%) 0.1958
Subsidized AA 0 (0%) 0 (0%) – 0 (0%) 1 (1%) –
Any ACT* 27 (44%) 65 (19%) 0.0008 4 (8%) 63 (17%) 0.0396
Any subsidized ACT* 22 (36%) 52 (15%) 00010 2 (5%) 38 (10%) 0.1883
Non-ACT antimalarials
Sulfadoxine-pyrimethamine 8 (14%) 33 (11%) 0.5127 4 (8%) 42 (11%) 0.6415
Amodiaquine 2 (2%) 1 (,1%) 0.0889 0 (0%) 11 (3%) –
Quinine 0 (0%) 9 (3%) – 1 (2%) 2 (,1%) 0.1975
Other medications
Paracetamol (acetaminophen) 45 (74%) 220 (70%) 0.6746 33 (84%) 311 (87%) 0.3352
Antibiotic 7 (12%) 35 (11%) 0.7394 6 (10%) 48 (11%) 0.7043
*Proportion differed significantly by malaria status, in at least one region.
doi:10.1371/journal.pone.0094074.t004
Figure 5. ACT Purchase Among Clients with Malaria Parasit-
emia Stratified by Age and Region. *Proportions differed
significantly between regions.
doi:10.1371/journal.pone.0094074.g005
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certification, training, and region were all highly correlated so they
could not be tested in a composite model to look at their
independent effects. We did find that in addition to receiving
ADDO certification, drug shop attendants were more likely to
have received training on subsidized ACTs in Mtwara as
compared to Mwanza. Although this was not found to be a
significant predictor in the model, it is clear that some component
of either drug shop attendant practice or client behavior led to
higher ACT sales in Mtwara, compared to Mwanza even after
controlling for availability of subsidized drugs, prior care, income,
and other factors measured in this study.
One limitation of this study is that it was completed in registered
drug shops, based on lists provided by the TFDA. The findings in
this study cannot be generalized to unregistered shops and other
retail stores where practices may differ. In addition, it is possible
drug shop attendants or clients that participated in this study may
have altered their behavior due to the presence of the study team.
Although the researchers remained outside of the drug shop and
only approached clients after their purchase had been completed,
it is possible that community members knew that medical
providers were present providing free diagnostic tests and
treatment for malaria and this may have altered typical patterns
of drug shop attendance or drug purchasing behaviors. We tried to
limit these biases by asking drug shop attendants and participants
not to share any specific details about the study with others, and by
limiting the time spent at each shop to one day.
Even with these limitations, this is currently the only study
reporting antimalarial use in the private sector in the setting of
subsidized ACTs and in the absence of malaria diagnostic testing.
Two recent studies in Uganda and Cameroon provide additional
evidence on parasite prevalence and antimalarial purchase from
medicine retailers, in settings without ACT subsidies [33,34]. The
proportion of clients that tested positive for malaria parasitemia
was higher in both studies compared to the Tanzania results: 27%
by blood slide in Uganda, and 24% by RDT in Cameroon.
Amongst drug shop clients who tested positive for malaria the
percentage receiving an ACT in those studies was similar in
Uganda (32%), but was actually higher in Cameroon (48%),
though this may have been in part due to the inclusion of
pharmacies as well as drug stores in the Cameroon study [34].
The high level of paracetamol use for malaria/fever treatment
in this study was likely influenced by its low price, which is
typically 0.03–0.06 USD per tablet. However, the persistent
popularity of non-ACT antimalarials is harder to explain by price
alone. The AMFm program was based on the idea that if ACTs
were available at the price of other inexpensive antimalarials, they
would crowd out other medications and would lead to increased
access to these essential medicines in rural communities where
access to public health facilities can be difficult [16,24]. In fact, an
independent evaluation of the AMFm program overall found it to
be quite a success by certain measures. In Tanzania and multiple
other countries, baseline and endline surveys revealed that the
subsidy was successful at decreasing the price, increasing the
availability and increasing the market-share of ACTs in the private
sector [20]. According to their evaluation, in mainland Tanzania
the median price of quality-assured ACTs in the private for-profit
sector decreased from 5.28 USD per adult equivalent treatment
dose at baseline in 2010 to 0.94 USD (2010 USD) after AMFm
implementation in 2011, identical to the endline price of SP, the
most widely purchased antimalarial at that time [20]. Findings
from this study are concerning in that, even with the success of the
ACT subsidy by these measures, the majority of drug shop clients
with malaria did not purchase ACTs in either region.
In addition, this study provides a basic assessment of how well
the subsidy may be utilized in the private sector in the absence of
diagnostic testing. With over 70% of ACTs purchased going to
clients who tested negative for malaria, this study highlights the
need for better targeting of ACTs. Studies in other settings have
shown that drug shop staff and community members are interested
in diagnostic testing and in RDTs becoming available at this level
[10,35–38]. Initial piloting of subsidized RDTs in drug shops in
Uganda in 2011 found that RDT quality, sales, and correct usage
were all maintained six months after drug shop attendants were
trained on their use, though notably ACT purchase amongst
persons who were RDT positive for malaria in that study was still
just 32% [22]. Experience with subsidized RDTs in the private
sector in Cambodia has also highlighted challenges in terms of
poor uptake by consumers, and the need to structure the relative
pricing of RDTs and ACTs to incentivize appropriate case
management [39].
Challenges with malaria case management, even after the
introduction of RDTs, have also been seen in the public sector.
Multiple studies in Tanzania have shown that implementing
policies requiring parasitological confirmation of malaria and
training healthcare workers on RDT use significantly decreases the
inappropriate prescription of antimalarial therapy, often times
associated with a corresponding rise in antibiotic prescription
[32,40–43]. One recent study in three regions in Tanzania
(including Mtwara and Mwanza) reported that even after RDT’s
were introduced in the public sector, only 55% of febrile patients
underwent laboratory testing for malaria and only 50% of patients
positive for malaria (by exit-interview blood film) obtained an
ACT [32]. Many questions remain about where private sector
diagnostic testing should be implemented, how it can best be
Figure 6. Malaria Parasitemia among Clients Who Purchased
ACTs Stratified by Age and Region. *Proportions differed
significantly between regions.
doi:10.1371/journal.pone.0094074.g006
Figure 7. Diagram of Persons with Malaria Parasitemia vs.
Persons who Purchased ACTs. *101 (13.0%) persons had malaria
parasitemia. 159 (20.5%) persons purchased ACTs. 31 (30.7%) of those
with malaria parasitemia purchased ACTs. 128 (80.5%) of those who
purchased ACTs did not have malaria parasitemia.
doi:10.1371/journal.pone.0094074.g007
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introduced (training, supervision, community messaging), how
these shops should be monitored, and what unintended conse-
quences might result. On-going pilots in Ghana, Nigeria, Uganda
and Zambia may provide the data that are needed to determine
where and how this can intervention can best be implemented
(Unpublished data/on-going trials).
Since this study was performed, Tanzania has completed the
expansion of the ADDO program to all regions. In addition, in
late 2012, the Global Fund discontinued its separate funding
stream for AMFm, and integrated the program into its core grant
management and financial processes. Countries are now respon-
sible for deciding whether or not to allocate Global Fund grants to
private sector ACT subsidies. Decisions will also need to be made
on whether or not to further initiate diagnostic testing in the
private sector as a complementary measure. The Tanzanian
government decided to continue with ACT subsidies, and to pilot
the introduction of subsidized and low-cost (price-negotiated)
RDTs in ADDOs in limited districts, in order to address the poor
targeting of ACTs highlighted in this paper. This may potentially
serve as a model for other countries that seek to support targeted
and appropriate malaria care in the private sector within a limited-
resource context.
Conclusion
This study assessed the relationship between laboratory or
parasitologically-confirmed malaria and ACT purchase in the
private sector in the setting of a national ACT subsidy program
and sub-national drug-shop training program. It showed that a
substantial proportion of patients presenting to drug shops have
malaria, and that even in the context of a national ACT subsidy
program, less than a third of persons with malaria obtained ACTs
in the private sector. It also showed that less than a quarter of
persons obtaining ACTs tested positive for malaria. Expanding
drug shop training and considering other measures of targeting
ACTs, such as making diagnostic tests available in drug shops,
should be considered to further improve access to and reduce
inappropriate use of essential malaria medicines in the private
sector in the future.
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